Abstract: Provided is a modified B-type natriuretic peptide (BNP) comprising a covalently attached polymer comprising amino acids, where the polymer inhibits degradation and/or elimination of the BNP in a subject, and where the modified BNP retains vasorelaxant activity. Nucleic acid molecules encoding the above-described modified BNP, as are vectors comprising the nucleic acid molecules, and cells comprising the vector. Methods of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition that can be treated with a natriuretic, diuretic or vasorelaxant is also provided. The methods comprise administering the above modified BNP to the subject. Further provided is method of preparing the above-described modified BNP.

Abstract: Certain amidophenyl-sulfanylamino-benzo[1,2,5]thiadiazole compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.

Abstract: There are provided by the present invention certain pyrazole based CCK-1 receptor modulators.

Abstract: The invention relates to nucleic acids and polypeptides referred to herein as cospeptin and cosmedin. Cospeptin, cosmedin, analogs and mimetics thereof act in signaling pathways, and are shown to modulate hypertension and other cardiovascular parameters, and gastric emptying. Cospeptin and cosmedin nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing the polypeptide; and in studying associated physiological pathways.